LPIN2 (lipin 2) encodes a phosphatidate phosphatase — an enzyme that converts phosphatidic acid to diacylglycerol, a critical branching point in the pathway that distributes lipids between triglyceride storage and phospholipid membrane synthesis. LPIN2 also acts as a transcriptional co-activator¹¹ LPIN2 also acts as a transcriptional co-activator
Like its paralog LPIN1, LPIN2 regulates expression of lipid metabolism genes in metabolic tissues including liver, adipose tissue, and skeletal muscle, making it a dual-function regulator of both lipid flux and gene expression.

The rs3745012 variant sits in the 3' untranslated region (3'UTR) of the LPIN2 mRNA — a region that controls mRNA stability, transcript longevity, and translation efficiency rather than the protein sequence itself. This is a regulatory variant: it doesn't change what LPIN2 protein does, but may alter how much of it your cells produce in response to nutritional and metabolic cues.

The Mechanism

LPIN2 is on the minus strand of chromosome 18. The 3'UTR variant rs3745012 has a reference allele of G on the plus strand, which corresponds to C on the coding (minus) strand — the allele the original research literature refers to when naming the risk variant. When the G (coding C) allele is present, alterations in 3'UTR regulatory sequences likely affect microRNA binding sites or RNA-binding protein interactions that control LPIN2 expression, particularly in adipose and liver tissue.

The clinical consequence operates through a striking gene-environment interaction²² gene-environment interaction
An interaction in which a genetic variant's effect on phenotype depends on an environmental exposure — here, body weight acts as the environmental modifier. In lean individuals, the G allele is neutral or even subtly protective. In overweight and obese individuals, the same G allele is associated with substantially elevated type 2 diabetes risk (OR 2.01) and an unfavorable shift in fat distribution: more trunk fat relative to leg fat. This trunk-predominant pattern of fat distribution — sometimes called central or visceral adiposity — is independently associated with insulin resistance, dyslipidemia, and cardiovascular disease.

The Evidence

The primary evidence comes from a 2007 study by Aulchenko et al.³³ 2007 study by Aulchenko et al.
Aulchenko YS et al. LPIN2 is associated with type 2 diabetes, glucose metabolism, and body composition. Diabetes. 2007 that examined rs3745012 in a two-stage design: discovery in a genetically isolated Dutch population (78 T2D cases, 101 controls) followed by replication in a larger Dutch general-population cohort (616 T2D cases, 2,890 controls). The C allele (plus-strand G) was associated with type 2 diabetes with an odds ratio of 2.01 (P = 0.03) in subjects with elevated BMI. A critical finding was the BMI interaction: in lean individuals, the same allele showed no association or a trend toward protection, while in overweight/obese individuals the risk was substantial (P = 0.02 for interaction with BMI).

The same study found that rs3745012 strongly affected the composite insulin sensitivity index in 361 normoglycemic individuals (P = 0.006 for overall effect, P = 0.004 for interaction), and was associated with increased trunk-to-legs fat mass ratio (P = 0.001) in a fat distribution sub-analysis of 836 individuals. This trunk adiposity association provides a plausible mechanistic link: altered LPIN2 function in adipose tissue shifts lipid partitioning toward visceral depots, which in turn impair hepatic insulin sensitivity.

A subsequent review of the lipin family Reue 2009⁴⁴ Reue 2009
Reue K. The lipin family: mutations and metabolism. Current Opinion in Lipidology. 2009 confirmed that LPIN2 polymorphisms are associated with insulin sensitivity, diabetes, blood pressure, and thiazolidinedione drug response in metabolic disease populations.

The evidence remains at the moderate level: the association is replicated within one large cohort and is biologically plausible given LPIN2's role in adipose lipid metabolism, but independent replication in additional populations has not been comprehensively reported.

Practical Actions

The clearest clinical implication of rs3745012 is that the risk is weight-contingent. For GG genotype carriers, maintaining healthy body weight is not merely a general health recommendation but a genotype-specific intervention that directly modulates whether this variant has metabolic consequences. The insulin sensitivity and fat distribution effects are most pronounced in obesity. Strategies that specifically target visceral adiposity — particularly reducing dietary refined carbohydrate and fructose, which preferentially drive hepatic lipogenesis — are mechanistically matched to LPIN2's role in lipid partitioning.

Interactions

This variant's effect is modified by body weight in a documented gene-environment interaction (P = 0.02 for the BMI interaction on T2D risk). Carriers of the GG genotype who also carry insulin-signaling risk variants — such as TRIB3 Q84R (rs2295490) or the IRS1 regulatory variant (rs1801282) — may face a compounded metabolic risk, since impaired Akt signaling (TRIB3/IRS1) and adverse fat partitioning (LPIN2) can synergistically worsen insulin resistance. This interaction has not been formally tested in published studies and would require a compound action to properly address.

TERT (telomerase reverse transcriptase) is the catalytic engine of telomerase, the molecular complex that rebuilds the protective caps (telomeres) at the ends of chromosomes after each cell division. The 5p15.33 genomic region — where TERT sits — is one of the most pleiotropic loci in the human genome, with multiple independent variants independently linked to diverse cancers, telomere length, and now psychiatric resilience. Rs4975605 is an intronic variant at this locus (chr5:1275413, GRCh38) that sits approximately 10 kilobases 5' of the better-characterized rs2736100 variant and appears to tag a distinct functional signal within the TERT regulatory landscape.

The Mechanism

Rs4975605 falls within intron 2 of TERT on the minus-strand gene, though the alleles are reported in forward (plus-strand) orientation: C (reference, common) and A (alternate, risk). Like other intronic TERT variants, it does not alter the protein sequence but is believed to influence TERT gene regulation through allele-specific effects on transcription factor binding or chromatin accessibility in specific tissues. The variant is in partial linkage disequilibrium¹¹ partial linkage disequilibrium
the degree to which this SNP tracks with neighboring TERT variants such as rs2736100, rs2736122, and rs10069690 varies by cancer type, suggesting it tags at least partly independent regulatory variation with neighboring TERT variants, meaning it captures partly distinct biological variation at this locus.

Notably, the biological associations of rs4975605 do not perfectly mirror those of rs2736100. The two variants appear to influence TERT regulation in a tissue- and context-dependent manner: rs4975605 shows stronger associations with germ cell tumors and ovarian cancers — tissues where telomerase reactivation is a near-universal early event — while rs2736100 has stronger associations with leukocyte telomere length and lung adenocarcinoma. This dissociation is biologically informative: the TERT locus contains multiple independent regulatory elements active in different cell types.

The Evidence

Testicular germ cell tumors (TGCT): The most precisely quantified association is with familial TGCT. Kratz et al. (2011, J Med Genet)²² Kratz et al. (2011, J Med Genet)
Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour studied 97 familial TGCT cases, 22 bilateral TGCT cases, and 871 controls, finding rs4975605 carried OR 1.68 (95% CI 1.23–2.29, p = 1.24 × 10⁻³) — a substantially elevated risk, notably described as a "second independent association" at the TERT locus beyond the primary signal at rs2853676/rs4246742. This independent signal suggests rs4975605 tags regulatory variation that compounds, rather than merely duplicates, the primary TERT risk at this locus.

Ovarian cancer: Terry et al. (2012, Cancer Epidemiol Biomarkers Prev)³³ Terry et al. (2012, Cancer Epidemiol Biomarkers Prev)
Telomere length and genetic variation in telomere maintenance genes in relation to ovarian cancer risk analyzed 2,112 ovarian cancer cases and 2,456 controls from two large US cohorts, finding rs4975605 among seven TERT SNPs that were significantly associated with ovarian cancer risk. The overall TERT gene-level association was p = 0.00008. Ovarian cancer, like TGCT, is a cancer type where telomerase reactivation is nearly universal and TERT gene regulation is particularly critical for tumor progression.

Lung cancer chemotherapy response: Zhao et al. (2015, PLoS One)⁴⁴ Zhao et al. (2015, PLoS One)
Association of TERT polymorphisms with clinical outcome of non-small cell lung cancer patients studied 1,004 patients with inoperable advanced NSCLC receiving first-line platinum-based chemotherapy. Heterozygous C/A carriers showed a dramatic reduction in clinical benefit rate compared to C/C homozygotes: 56.4% versus 82.9% (adjusted OR 3.58, p = 1.40 × 10⁻⁴). The effect was most pronounced in never-smoking female patients, a subgroup that has distinct TERT biology. This finding is clinically relevant but requires replication in independent cohorts.

Paranoid schizophrenia — a protective association: Rao et al. (2016, Am J Med Genet B)⁵⁵ Rao et al. (2016, Am J Med Genet B)
Variants in TERT influencing telomere length are associated with paranoid schizophrenia risk conducted a case-control study in 1,072 schizophrenia cases and 1,284 controls from a Chinese Han population. The A allele of rs4975605 was associated with significantly reduced schizophrenia risk (OR 0.73, 95% CI 0.60–0.90, p = 0.0026). Mean lymphocyte telomere length was shorter in schizophrenia patients across the sample — consistent with a model in which TERT variants influencing telomere maintenance modulate neurodevelopmental resilience in ways that affect psychiatric disease liability. Notably, a different TERT variant (rs2075786) in the same study correlated directly with telomere length per genotype, but rs4975605's protective effect was not fully explained by telomere length alone, suggesting it may act through additional mechanisms.

No association with colorectal cancer: Hofer et al. (2012, Mol Carcinog)⁶⁶ Hofer et al. (2012, Mol Carcinog) found no significant association with colorectal cancer or polyp risk among seven TERT SNPs including rs4975605, suggesting the variant's cancer associations are tissue-specific.

Practical Actions

The dual nature of rs4975605 — increased cancer risk in germ cell and ovarian cancers, but protection against schizophrenia — reflects the broader TERT paradox: higher telomerase activity supports proliferating cell survival, which can be beneficial (neuronal maintenance, tissue homeostasis) or harmful (enabling cancer). For A allele carriers, the cancer associations are modest at the individual variant level and most clinically meaningful when considered alongside family history and other TERT locus variants. The chemotherapy response finding has direct implications for NSCLC patients considering platinum-based regimens.

Interactions

rs2736100 (TERT, intron 2, chr5:1,285,974): The best-characterized TERT longevity-cancer variant, with direct effects on leukocyte telomere length and strong associations with lung adenocarcinoma, glioma, and myeloproliferative neoplasms. Rs4975605 and rs2736100 are in partial but incomplete LD — combined risk alleles at both loci may represent additive burden on TERT regulatory function in susceptible tissues.

rs2853676 (TERT): Another independent TERT signal for testicular and other cancers. Kratz et al. identified the primary testicular cancer TERT signal at rs2853676/rs4246742, with rs4975605 as an additional independent signal, suggesting these variants capture different aspects of TERT regulation in the germline.

rs10069690 (TERT): An intronic variant associated with ovarian cancer, triple-negative breast cancer, and telomere-related cancers. In the Terry et al. ovarian cancer study, rs10069690 and rs4975605 were both among the TERT SNPs significantly associated with risk, suggesting possible interaction or pathway-level burden.

Most people never know they carry a dangerous reaction waiting inside their muscle cells—until the moment a surgeon reaches for a gas mask. Malignant hyperthermia (MH) is a pharmacogenetic crisis of skeletal muscle¹¹ a pharmacogenetic crisis of skeletal muscle
triggered only by specific anesthetic drugs in genetically susceptible individuals. The rs63749869 variant in the RYR1 gene is one of the most well-characterized causes. A carrier who receives a routine volatile anesthetic—sevoflurane, isoflurane, halothane, desflurane—or the muscle relaxant succinylcholine can experience a life-threatening cascade of heat, acid, and rhabdomyolysis within minutes of induction. Before dantrolene became available, the mortality rate exceeded 70%. With prompt treatment it is now under 5%—but only if the anesthesia team knows to act.

The Mechanism

RYR1 encodes the ryanodine receptor 1, the calcium release channel of the skeletal muscle sarcoplasmic reticulum²² calcium release channel of the skeletal muscle sarcoplasmic reticulum
the intracellular calcium store that controls muscle contraction. In a healthy muscle fiber, this channel opens transiently to trigger contraction, then closes. The rs63749869 G>A substitution changes arginine to histidine at position 4861 of the protein (p.Arg4861His), destabilizing the channel's closed state. When a volatile anesthetic molecule binds near this domain, the mutant channel opens uncontrollably and floods the cytoplasm with calcium³³ floods the cytoplasm with calcium
sustained calcium release drives relentless ATP consumption, heat production, and membrane breakdown. The resulting hypermetabolic spiral—rising CO₂, rising temperature, rigidity, acidosis, rhabdomyolysis, hyperkalemia—is fatal without intervention.

Cryo-EM structural mapping of RYR1 shows that pathogenic MHS variants cluster at specific regulatory domains distinct from the pore-forming region implicated in central core disease. The Arg4861 residue lies in this MHS-associated regulatory region, explaining why rs63749869 carriers often show isolated MHS susceptibility without chronic muscle weakness—the channel destabilization is pharmacologically triggered rather than constitutively active.

The Evidence

ClinVar classifies this variant as Pathogenic across multiple submissions (2-star review status, multiple independent submitters including OMIM, Mass General Brigham, and GeneDx), with documented associations to central core myopathy (RCV000013852), general RYR1-related disorder (RCV000119533), and malignant hyperthermia of anesthesia (RCV004017241). In silico predictions are strongly damaging (REVEL: 0.91; 3Cnet: 0.99).

A 2022 expert panel review⁴⁴ 2022 expert panel review
Johnston et al. Human Mol Genet 2022 — classified 251 RYR1 variants using updated VCEP criteria estimated the prevalence of pathogenic RYR1-related MHS at 1 in 300 to 1 in 1,075 individuals—far higher than the 1:5,000–1:50,000 rate of actual MH reactions, because most carriers undergo surgery without triggering exposure or with insufficient volatile agent to cross the crisis threshold.

Snoeck et al. 2015⁵⁵ Snoeck et al. 2015
Dutch multicenter cohort of 77 RYR1-mutation patients across all ages documented the phenotypic spectrum: isolated MH susceptibility, non-anesthesia rhabdomyolysis triggered by vigorous exercise or heat exposure, and congenital myopathy with permanent weakness. The same variant can cause dominant MHS in one family member and recessive myopathy in another—a reminder that penetrance and expressivity vary substantially.

In gnomAD v4 exomes (>400,000 individuals sequenced), this specific allele appears just once across 805,810 chromosomes, confirming its extreme rarity in the general population and its high clinical penetrance when present.

Practical Actions

The most important thing a carrier can do is tell every anesthesiologist before any procedure. Volatile anesthetics (halothane, isoflurane, sevoflurane, desflurane, enflurane) and the depolarizing muscle relaxant succinylcholine must be avoided entirely. Safe alternatives exist: total intravenous anesthesia (TIVA) using propofol, ketamine, opioids, and non-depolarizing muscle relaxants (vecuronium, rocuronium) carries no MH risk for RYR1 carriers. Regional anesthesia (spinal, epidural, nerve blocks) is also safe and preferable when appropriate for the procedure.

Carry a medical alert card or wear a medical alert bracelet identifying yourself as MH-susceptible. The Malignant Hyperthermia Association of the United States (MHAUS)⁶⁶ Malignant Hyperthermia Association of the United States (MHAUS) provides wallet cards and maintains a 24/7 hotline (1-800-644-9737) for anesthesia professionals managing crises.

First-degree relatives (parents, siblings, children) have a 50% chance of carrying the same autosomal dominant variant. Genetic testing of family members—a simple blood draw—can identify who shares the risk before they encounter surgery.

Non-anesthesia triggers are less common but documented: extreme exertion in high ambient heat can precipitate exercise-induced rhabdomyolysis⁷⁷ exercise-induced rhabdomyolysis
muscle breakdown releasing myoglobin, potassium, and creatine kinase into the bloodstream in some RYR1 carriers. If you experience unexpected dark urine, severe muscle pain, or extreme weakness after intense exercise, seek emergency evaluation for rhabdomyolysis.

Interactions

The RYR1 gene harbors hundreds of variants associated with malignant hyperthermia susceptibility and central core disease. rs63749869 (p.Arg4861His) acts through the same channel-destabilization mechanism as other MHS variants in the N-terminal and central regulatory domains. The combined phenotype of compound heterozygosity for two RYR1 variants—one on each chromosome—often produces a more severe recessive myopathy phenotype (congenital weakness, respiratory involvement) rather than isolated MHS. Related variants worth noting include rs118192172 (p.Arg163Cys, a classic MHS hotspot), rs28933400 (p.Gly341Arg), and the many ClinVar-pathogenic MHS alleles catalogued in OMIM entry 180901.

Your body cannot synthesize vitamin C. Every molecule of ascorbate¹¹ ascorbate
The biologically active, ionized form of ascorbic acid at physiological pH — the form actively transported across cell membranes in your bloodstream was absorbed from food by your intestine and then conserved by your kidneys. Both steps depend on SVCT1²² SVCT1
Sodium-dependent Vitamin C Transporter 1 — encoded by SLC23A1 on chromosome 5q23.2, expressed on the apical membrane of intestinal enterocytes and proximal renal tubule cells, the transporter encoded by SLC23A1. rs6596471 is an intronic variant in this gene that was identified as one of four SLC23A1 variants assessed in a landmark population study of circulating vitamin C concentrations. The G allele represents an independent haplotype effect on transporter function that is distinct from — and likely additive with — the well-characterized Val264Met missense variant at the same gene.

The Mechanism

rs6596471 falls in an intron of SLC23A1 at GRCh38 position chr5:139,369,899. The gene itself sits on the minus strand, but genome files report the plus-strand alleles (A reference, G alternate). Intronic variants exert their effects through regulatory rather than protein-coding mechanisms: they can alter splice enhancer or silencer sequences³³ splice enhancer or silencer sequences
Short sequence motifs within introns that recruit splicing regulatory proteins, influencing how efficiently exons are joined during pre-mRNA processing. Variants in these regions can alter the ratio of functional splice isoforms, intronic secondary promoters, mRNA stability elements, or binding sites for RNA-binding proteins. The net result is a measurable change in SVCT1 protein output at the intestinal epithelium and proximal kidney tubule — reducing both dietary vitamin C absorption and the renal reabsorption that prevents filtered ascorbate from being lost in urine.

The biological importance of SVCT1 is dramatically illustrated by knockout mouse experiments⁴⁴ knockout mouse experiments
Corpe CP et al. Vitamin C transporter Slc23a1 links renal reabsorption, vitamin C tissue accumulation, and perinatal survival in mice. J Clin Invest, 2010: mice completely lacking Slc23a1 excrete 18 times more ascorbate in urine than controls and 45% of offspring die perinatally. rs6596471 represents a partial perturbation of the same system — measurable, not catastrophic, but clinically relevant at the population level.

The Evidence

rs6596471 was included in the discovery phase of a landmark meta-analysis⁵⁵ landmark meta-analysis
Timpson NJ et al. Genetic variation at the SLC23A1 locus is associated with circulating concentrations of L-ascorbic acid (vitamin C): evidence from 5 independent studies with >15,000 participants. Am J Clin Nutr, 2010 that pooled data from five independent UK cohorts (15,087 participants total). The paper assessed four variants across the SLC23A1 locus — rs6596471, rs6596473, rs33972313, and rs10063949 — to characterize the genetic architecture of this region. While rs33972313 (Val264Met) emerged as the primary confirmed signal in the pooled meta-analysis (~6 µmol/L reduction per minor allele, P = 2.0×10⁻⁷), the assessment of rs6596471 in the discovery phase reflects its role as a marker for a distinct haplotype class at the locus. Different variants in the same gene can independently tag different functional changes in transporter regulation.

The broader genetic landscape was mapped in a GWAS of 52,018 European individuals⁶⁶ GWAS of 52,018 European individuals
Zheng JS et al. Plasma Vitamin C and Type 2 Diabetes: Genome-Wide Association Study and Mendelian Randomization Analysis in European Populations. Diabetes Care, 2021 that identified 11 genome-wide significant loci for plasma vitamin C — with SLC23A1 producing the strongest signal of any locus. The same locus was independently confirmed in the EPIC cohort study⁷⁷ EPIC cohort study
Duell EJ et al. Vitamin C transporter gene (SLC23A1 and SLC23A2) polymorphisms, plasma vitamin C levels, and gastric cancer risk in the EPIC cohort. Genes Nutr, 2013 (365 gastric cancer cases, 1,284 controls), which found multiple SLC23A1 variants each independently predicting circulating ascorbate concentrations after accounting for dietary intake.

Mendelian randomization studies using SLC23A1 variants as genetic instruments have consistently found that genetically lower vitamin C does not causally drive cardiovascular disease, type 2 diabetes, or other cardiometabolic outcomes — indicating that observational associations between low vitamin C and disease risk largely reflect dietary confounding rather than direct vitamin C deficiency pathology.

Practical Actions

The frequency of the G allele at rs6596471 varies considerably by ancestry: about 25% in Europeans (so GG homozygosity affects ~6% of Europeans) versus 78% in East Asians. For G allele carriers, the practical implication parallels other SLC23A1 variants: reduced SVCT1 efficiency means a higher dietary vitamin C intake is needed to maintain the same plasma ascorbate level as someone with two reference copies. The body cannot compensate by making its own vitamin C — it can only absorb what arrives in the gut and retain what passes through the kidney.

Practical strategies focus on providing more substrate to the transporter (higher dietary intake and supplementation) and on verifying adequacy with plasma ascorbate measurement. Single large doses of supplemental vitamin C are inefficient because intestinal absorption saturates at approximately 200 mg per dose regardless of genotype. Distributing intake across the day is more effective for maintaining plasma levels.

Interactions

rs6596471 operates at the same gene and same physiological step as rs33972313 (the Val264Met missense variant) and rs11950646 (another intronic regulatory signal). These are independent haplotype markers at the SLC23A1 locus: a person carrying risk alleles at multiple positions would be expected to show a larger reduction in SVCT1 output than any single variant alone. Separately, the SLC23A2 gene (which encodes SVCT2, the tissue-level transporter responsible for vitamin C delivery to the brain, adrenal glands, and eyes) harbours its own independent regulatory variants (rs6053005, rs6133175, rs1279683). Carrying risk alleles at both SLC23A1 (absorption + renal reabsorption) and SLC23A2 (tissue delivery) would be expected to produce a compounded reduction in tissue-level vitamin C, though this specific combination has not been directly studied.

Plasminogen is the body's master clot-dissolving precursor. Secreted by the liver and distributed throughout the bloodstream and mucosal tissues, it is activated to plasmin¹¹ plasmin
the active serine protease that cleaves fibrin, dissolves clots, and clears debris from injured mucosal surfaces wherever the body needs to remodel or repair tissue. In the middle ear, this fibrinolytic activity is essential — infections naturally produce fibrin as part of the inflammatory response, and plasmin dissolves it before it accumulates into permanent, obstructive deposits.

The Lys38Glu variant (c.112A>G, historically called K19E before signal peptide corrections standardized numbering) swaps a positively charged lysine for a negatively charged glutamic acid at position 38 of the mature protein, located in the PAN/Apple domain. This is the most common disease-causing mutation in the PLG gene worldwide, found in 34% of alleles among documented plasminogen deficiency patients. The variant impairs the protein's secretion from liver cells — mutant plasminogen is retained and degraded rather than efficiently released into circulation — leaving mucosal surfaces chronically short of the fibrinolytic activity they need.

The Mechanism

When plasminogen levels fall sufficiently, fibrin cannot be cleared from inflamed mucosal surfaces at the rate it is deposited. The result is the accumulation of ligneous (woody) pseudomembranes²² ligneous (woody) pseudomembranes
thick, fibrin-rich masses that replace normal mucosal tissue with a wood-like material; "ligneous" derives from the Latin for wood, describing their texture. In the middle ear, uncleaned fibrin creates an ideal matrix for bacterial colonization and chronic infection. In mouse models, complete plasminogen deficiency causes 100% of animals to develop chronic otitis media³³ complete plasminogen deficiency causes 100% of animals to develop chronic otitis media
with bacterial colonization by five different species, extensive fibrin deposition, and neutrophil/macrophage infiltration — all within 18 weeks.

The Lys38Glu variant in humans is not a null allele — heterozygous carriers have residual plasminogen activity and mostly do not develop overt ligneous disease. The clinical spectrum runs from asymptomatic carriers (one functional copy is usually enough for adequate fibrinolysis) through increased susceptibility to recurrent otitis media, to severe ligneous conjunctivitis and other mucosal pseudomembranes in compound heterozygotes or homozygotes who carry two loss-of-function alleles.

The Evidence

The landmark clinical series by Tefs et al. in Blood (2006), covering 50 patients with confirmed type I plasminogen deficiency⁴⁴ Tefs et al. in Blood (2006), covering 50 patients with confirmed type I plasminogen deficiency
largest cohort study to date, across multiple countries, established Lys38Glu as the most prevalent disease allele worldwide (34% of pathogenic PLG alleles in the cohort). Otitis media was a documented manifestation in 14% of these patients — the fourth most common mucosal site after eyes (80%), gums (34%), and respiratory tract (16%).

At the population level, the 23andMe GWAS of over 200,000 Europeans identified the PLG locus as genome-wide significantly associated with childhood ear infection susceptibility⁵⁵ identified the PLG locus as genome-wide significantly associated with childhood ear infection susceptibility
OR=1.43, p<5×10⁻⁸, from the landmark 2017 Nature Communications GWAS of 23 common infections. An OR of 1.43 is unusually high for a common infection GWAS — most GWAS hits for infectious disease susceptibility show ORs in the 1.1–1.2 range — reflecting the direct mechanistic link between PLG function and middle ear fibrin clearance.

A targeted multi-omic study of 718 otitis-prone families identified the Lys38Glu variant in four multi-ethnic families showing an autosomal dominant pattern with reduced penetrance⁶⁶ identified the Lys38Glu variant in four multi-ethnic families showing an autosomal dominant pattern with reduced penetrance
Bootpetch et al., Scientific Reports 2020, reinforcing the biological plausibility even though the smaller family-based TDT did not reach statistical significance.

In the clinical setting, type I plasminogen deficiency is diagnosed in approximately 1.6 per million individuals⁷⁷ type I plasminogen deficiency is diagnosed in approximately 1.6 per million individuals
Shapiro & Nakar, Blood 2025, with the diagnosis frequently delayed because early presentations mimic common conditions — clinicians often attribute repeated ear infections to Eustachian tube dysfunction, adenoid hypertrophy, or daycare exposure before the underlying fibrinolytic defect is recognized.

Practical Implications

For carriers of a single Lys38Glu allele (AG genotype), the risk is a modest elevation in recurrent ear infection susceptibility, not overt plasminogen deficiency. One functional PLG copy is generally sufficient to maintain near-normal fibrinolysis; the association observed in the GWAS likely reflects heterozygous dosage effects on mucosal fibrin clearance during infections.

For those with two risk alleles (GG) or those who are compound heterozygotes (one Lys38Glu allele plus a different loss-of-function PLG allele not captured by this SNP), the clinical picture shifts significantly: plasminogen levels can fall to 5–17% of normal, and ligneous pseudomembranes can form across multiple mucosal surfaces simultaneously. The FDA approved an intravenous human plasma-derived plasminogen concentrate (Ryplazim) in 2021 — the first specific treatment for this condition.

Recurrent otitis media in a child with an ear infection history that seems disproportionate to typical risk factors — particularly if there are also eye, gum, or respiratory membrane abnormalities — warrants plasminogen level testing.

Interactions

The pathogenicity of Lys38Glu depends strongly on the status of the second PLG allele. Compound heterozygosity — carrying Lys38Glu on one chromosome and a different pathogenic PLG mutation (stop, frameshift, splice site, or other missense) on the other — produces much lower residual plasminogen activity than heterozygosity for Lys38Glu alone. Individuals in families with known plasminogen deficiency should consider comprehensive PLG sequencing rather than relying on this single rsid to characterize their risk.

No gene-gene interaction compound actions are proposed at this time, as the primary clinical modifier is the second PLG allele (not captured in a single-variant GWAS entry).

This variant, together with rs429358, determines your APOE genotype. The rs7412 variant causes a missense change at position 176 of the APOE protein, substituting arginine with cysteine (p.Arg176Cys). This defines the APOE ε2 isoform.

The Mechanism

The E2 isoform has reduced affinity for the LDL receptor compared to E3, which paradoxically leads to lower LDL cholesterol in most carriers. The arginine-to-cysteine substitution alters the protein's lipid-binding properties, generally leading to more efficient cholesterol clearance from the bloodstream.

The Evidence

The E2 allele is generally protective for cardiovascular health. E2 carriers typically have lower LDL cholesterol and better lipid profiles overall. A large neuropathological study¹¹ large neuropathological study
Reiman et al. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes. Nat Commun, 2020 of over 5,000 individuals confirmed that E2/E2 homozygotes have exceptionally low Alzheimer's risk — roughly 40% lower than E3/E3.

However, the rare E2/E2 genotype (~1% of the population) can sometimes be associated with type III hyperlipoproteinemia²² A rare lipid disorder (OMIM #617347) where cholesterol-rich remnant particles accumulate, causing yellowish skin deposits and elevated cardiovascular risk, particularly when combined with other metabolic triggers such as obesity, diabetes, or hypothyroidism.

Practical Implications

The E2 allele is generally protective for cardiovascular health and Alzheimer's disease. E2 carriers typically have lower LDL cholesterol and better lipid profiles overall. However, the rare E2/E2 genotype (~1% of the population) can sometimes be associated with type III hyperlipoproteinemia, particularly when combined with other metabolic triggers such as obesity, diabetes, or hypothyroidism.

Interactions

The rs7412 and rs429358 variants together determine your complete APOE genotype (E2/E2, E2/E3, E3/E3, E3/E4, E2/E4, or E4/E4), which has implications for both cardiovascular health and Alzheimer's risk.

Every heartbeat is a precisely timed surge of calcium flooding the cardiac muscle cell, binding to troponin C, and pulling troponin T¹¹ troponin T
Cardiac troponin T (encoded by TNNT2) is the tropomyosin-binding subunit of the troponin complex — it anchors the regulatory machinery to the thin filament and transmits the calcium signal into mechanical force into a conformation that lets the myosin motors fire. When calcium retreats, troponin T reverts, the motors disengage, and the heart relaxes. The TNNT2 R141W variant — an arginine-to-tryptophan substitution at codon 141 (or 151, depending on transcript isoform) — breaks this feedback loop by making the troponin T–tropomyosin complex abnormally stable. The motors do not disengage as completely; the heart struggles to generate force proportional to the available calcium signal. The result is dilated cardiomyopathy (DCM)²² dilated cardiomyopathy (DCM)
Dilated cardiomyopathy: the left ventricle enlarges and weakens, reducing pump efficiency. In genetic forms, onset often occurs in the second to fourth decade and can progress to heart failure, arrhythmia, or sudden death — and in some families, left ventricular noncompaction (LVNC).

The variant is classified Pathogenic/Likely pathogenic by ClinVar (VCV000012414) with 16 of 20 independent submitters in agreement and a two-star review status. OMIM lists it as allelic variant 191045.0007. It is absent from gnomAD population databases at meaningful frequency, consistent with a disease allele under strong negative selection.

The Mechanism

Arginine 141 sits within the tropomyosin-binding domain³³ tropomyosin-binding domain
The region of TNNT2 that physically contacts alpha-tropomyosin along the thin filament; mutations here alter how tightly the troponin complex holds tropomyosin in the "off" position of cardiac troponin T. The arginine residue is positively charged and normally forms a salt bridge with glutamic acid 257 of alpha-tropomyosin. Replacing it with tryptophan — a bulky, hydrophobic residue — destroys this salt bridge and instead locks tropomyosin into an over-stabilized interaction with troponin T; quartz-crystal microbalance experiments⁴⁴ quartz-crystal microbalance experiments
A technique that measures binding kinetics between purified proteins with nanogram sensitivity by detecting changes in oscillation frequency as mass accumulates on a crystal surface showed the R141W mutation increases troponin T affinity for alpha-tropomyosin approximately three-fold compared to wild-type.

The functional consequence is paradoxical: stronger troponin T–tropomyosin binding makes it harder to open the thin filament, not easier. Troponin I, the inhibitory subunit, retains the thin filament more effectively in the blocked state, requiring higher intracellular calcium concentrations to generate the same contractile force — a state called calcium desensitization⁵⁵ calcium desensitization
Reduced myofilament sensitivity to calcium: the heart must work harder to sustain output, which over time drives maladaptive remodeling — chamber dilation, fibrosis, and impaired systolic function.

The Evidence

Lu et al., 2003⁶⁶ Lu et al., 2003
Lu QW et al., J Mol Cell Cardiol 2003;35:1377–83 — in vitro reconstitution with recombinant human TNNT2 R141W and alpha-tropomyosin; quartz-crystal microbalance binding assays and skinned fiber mechanics in rabbit cardiac muscle provided the first molecular explanation for R141W's DCM mechanism: three-fold tighter tropomyosin binding and direct demonstration of reduced Ca²⁺ sensitivity of force development.

Ramratnam et al., 2016⁷⁷ Ramratnam et al., 2016
Ramratnam M et al., PLoS One 2016;11(12):e0167681 — gene-targeted knock-in mouse model (Tnnt2^R141W/+); optical mapping, echocardiography, skinned fiber mechanics, and β-adrenergic stress testing in heterozygous mice demonstrated that heterozygous mice develop overt DCM with left ventricular dilation, reduced contractility, and significant Ca²⁺ desensitization. Hearts compensated by raising peak systolic calcium transient amplitude by 54% above wild-type — but this compensation prolonged the diastolic calcium fall and impaired cardiac responses to stress. Male mice had significantly worse survival than females (P<0.001), suggesting sex-modifying factors.

Hershberger et al., 2009⁸⁸ Hershberger et al., 2009
Hershberger RE et al., Circ Cardiovasc Genet 2009;2(4):306–13 — bidirectional resequencing of TNNT2 in 313 DCM probands; functional testing in porcine cardiac fiber preparations found TNNT2 mutations in 2.9% of DCM probands, characterized by early-onset aggressive disease (median onset 32.5 years) with Ca²⁺ desensitization as the consistent functional hallmark. The R141W variant was found in 3 individuals with DCM and segregated with disease in 16 affected relatives from 2 families; it also occurred de novo in one individual with LVNC — the first documented de novo R141W case.

Klaassen et al., 2008⁹⁹ Klaassen et al., 2008
Klaassen S et al., Circulation 2008;117(22):2893–901 — systematic sequencing of MYH7, ACTC, and TNNT2 in 63 unrelated adult LVNC probands identified heterozygous sarcomeric mutations in 11 of 63 cases (17%), including one TNNT2 mutation, establishing that the same sarcomeric gene variants that cause HCM and DCM can also present as LVNC — a phenotypically distinct condition sharing overlapping genetic architecture.

An iPSC model of pediatric DCM from TNNT2 R151W confirmed the calcium desensitization and sarcomere disorganization in patient-derived cardiomyocytes, and showed that overexpression of wild-type TNNT2 partially rescued the contractile defect — early evidence supporting future gene-therapy approaches.

Practical Actions

The autosomal dominant nature of R141W means a single copy is sufficient to cause disease. Each first-degree relative of a carrier has a 50% chance of inheriting the variant. Penetrance is high but variable: in the original R141W family, 5 of 19 carriers were phenotypically unaffected at evaluation ages ranging from 1 to 47 years, indicating that age-dependent penetrance and environmental modifiers influence expression.

Cardiac management follows current DCM and LVNC guidelines: establish baseline left ventricular dimensions and function, monitor for arrhythmias (atrial fibrillation affects 25–30% of LVNC patients; ventricular arrhythmias drive sudden death risk), consider anticoagulation (thromboembolism risk in LVNC is 21–38% over a lifetime), and use guideline-directed heart failure therapy (ACE inhibitors/ARBs, beta-blockers, diuretics) once systolic dysfunction develops.

Interactions

The R141W mutation has been reported in combination with an MYPN (myopalladin) S1296T variant in a family with severe LVNC — the compound digenic combination appeared to produce a more penetrant noncompaction phenotype than either variant alone, with Tnnt2 R141W/+ mice (but not Mypn S1296T/+ mice) showing cardiac hypertrabeculation and noncompaction in the murine model.

Other sarcomeric gene mutations in MYH7 (rs104894664), TPM1 (rs104894502, rs104894503), MYBPC3 (rs36211723), and ACTC (rs193922385) can produce overlapping DCM/LVNC/HCM phenotypes. "Double positive" sarcomeric genotypes — two pathogenic variants in different sarcomeric genes — are associated with earlier onset and more severe disease.

Intracranial aneurysms — balloon-like dilations of cerebral arteries¹¹ balloon-like dilations of cerebral arteries
abnormal sac-like outpouchings that form at vessel bifurcations, most commonly in the circle of Willis — affect roughly 3% of the general population. Most remain silent throughout a person's lifetime, but rupture causes a sudden and devastating subarachnoid hemorrhage with mortality exceeding 40% and permanent disability in half of survivors. Identifying who carries elevated genetic susceptibility is a clinically meaningful step toward targeted surveillance.

The rs767603 variant sits on chromosome 14 at position 60,631,965 (GRCh38), within a genomic region mapped to the ANIB8 susceptibility locus (OMIM 612162). The locus is annotated near LOC105378189, a long non-coding RNA (lncRNA) gene of uncertain function. The variant has no protein-coding consequence — it sits in regulatory sequence, potentially influencing the expression of nearby genes involved in vascular wall maintenance.

The Mechanism

LOC105378189 is a computationally predicted lncRNA at chromosome 14q23. Long non-coding RNAs in vascular tissue have been shown to regulate vascular smooth muscle cell phenotype, endothelial function, and extracellular matrix remodeling²² regulate vascular smooth muscle cell phenotype, endothelial function, and extracellular matrix remodeling
roles reviewed for lncRNAs ANRIL, H19, and lincRNA-p21 in arterial wall biology. The precise mechanism by which rs767603 influences aneurysm susceptibility is not established. The variant is believed to act as a regulatory tag — altering the expression of one or more genes at the 14q23 locus that govern vascular wall integrity, elastin organization, or smooth muscle cell contractility.

Genome-wide association studies of intracranial aneurysm have consistently implicated loci related to endothelial function and extracellular matrix maintenance. The chromosome 14q23 region overlaps with regulatory elements identified in endothelial cells, consistent with the broader observation that intracranial aneurysm heritability is enriched in endothelial cell epigenetic marks³³ intracranial aneurysm heritability is enriched in endothelial cell epigenetic marks
Bakker et al. Nature Genetics 2020, heritability enrichment analysis pointing to endothelial cell open chromatin.

The Evidence

The primary evidence for rs767603 comes from a Japanese case-control study by Mineharu et al. 2008⁴⁴ Mineharu et al. 2008
Association analyses confirming a susceptibility locus for intracranial aneurysm at chromosome 14q23, J Hum Genet 53:325–332. Using GeneChip 10K array genotyping in 29 patients with intracranial aneurysm from a geographically clustered Japanese community (Akita) and 35 controls, the study identified rs767603 as the sole variant reaching Bonferroni-corrected significance. The association was confirmed by both allelic analysis (p=0.00017, Bonferroni p=0.021) and haplotype analysis (p=0.00178, Bonferroni p=0.048). Crucially, the finding replicated in an independent nationwide Japanese cohort of 237 aneurysm patients and 253 controls (allelic p=0.0046, haplotype p=0.0060).

Chromosome 14q23 was independently supported by linkage analysis in two large familial aneurysm kindreds showing a parametric LOD score of 3.0 between markers rs2359991 and rs2373098, flanking the rs767603 region⁵⁵ flanking the rs767603 region
molecular genetic analysis linking chromosome 14q23-31 to familial intracranial aneurysm in Dutch and Finnish pedigrees.

The evidence level is classified as moderate: the association is replicated within a Japanese population and supported by independent linkage data, but large-scale multi-ancestry GWAS have not singled out rs767603 as a lead SNP in European populations, and no functional annotation (eQTL, chromatin accessibility, protein interaction) has been reported for this variant.

Practical Actions

For individuals carrying the T allele — particularly TT homozygotes — the most clinically useful action is enhanced cardiovascular surveillance. Clinical guidelines recommend MRI angiography (MRA) screening for first-degree relatives of known aneurysm patients, especially those with a history of hypertension or smoking. Genetic susceptibility adds independent information that can inform the timing and frequency of surveillance.

Blood pressure control is the most modifiable environmental factor for aneurysm growth and rupture risk. Hypertension accelerates the hemodynamic stress on arterial walls that promotes aneurysm formation and enlargement. For T-allele carriers, maintaining tightly controlled blood pressure — ideally below 130/80 mmHg — is a genotype-informed priority.

Smoking is the strongest modifiable environmental risk factor for intracranial aneurysm formation and rupture, independent of genetics. Genetic susceptibility and smoking act synergistically — the combination of rs767603 T-allele status and active smoking substantially elevates absolute risk beyond either factor alone.

Interactions

The 14q23 susceptibility locus for intracranial aneurysm overlaps in pathway terms with other established aneurysm risk loci, including rs1333040 at 9p21 (a robustly replicated IA locus near CDKN2A/B), and loci on chromosomes 10q24, 13q13, and 2q33 identified in large-scale European GWAS. These variants likely act through convergent mechanisms — endothelial dysfunction, smooth muscle phenotype switching, and extracellular matrix remodeling — rather than direct gene-gene epistasis. No documented compound interaction between rs767603 and other aneurysm SNPs has been studied.

SOX17 is not a structural gene — it is a master regulator. SOX17¹¹ SOX17
SRY-related HMG-box 17: a transcription factor essential for specification and maintenance of endothelial cell identity during embryonic and adult vascular development encodes a transcription factor that directly controls the genetic programs that make endothelial cells — the cells lining every blood vessel in the body — what they are. When SOX17 expression is altered, the endothelial monolayer loses integrity, vessel walls weaken, and the hemodynamic stresses of arterial blood flow become harder to contain. rs9298506 is a regulatory tag variant located approximately 64 kilobases downstream of the SOX17 coding sequence at chromosome 8q11.23. It does not change the SOX17 protein directly, but by sitting in regulatory sequence it can influence how much SOX17 is produced — with consequences for vascular wall maintenance throughout life.

The Mechanism

SOX17 regulates endothelial cell fate from embryogenesis through adulthood. It targets genes that govern endothelial junction integrity, vascular smooth muscle cell communication, and extracellular matrix remodeling. Arterial branch points — particularly those in the cerebral circulation where intracranial aneurysms preferentially form — experience the highest hemodynamic shear stress in the body. SOX17 expression maintains the shear-stress response program²² SOX17 expression maintains the shear-stress response program
Loss-of-function experiments show that SOX17-depleted endothelial cells fail to upregulate junction proteins and are more prone to inflammatory activation under flow conditions. When this transcriptional program is subtly impaired by a regulatory variant, the cumulative effect over decades may be a vessel wall that is marginally less resistant to aneurysm formation.

The GWAS Catalog annotates rs9298506 near the RP1 gene (8q12.1), but the 2008 Bilguvar discovery team explicitly noted that associated SNPs on 8q "likely act via SOX17, which is required for formation and maintenance of endothelial cells, suggesting a role in development and repair of the vasculature." The variant's position and the biological plausibility of SOX17 as the effector gene make this the most mechanistically coherent explanation. Heritability enrichment analysis³³ Heritability enrichment analysis
identifying which cell types' open chromatin regions explain the most GWAS signal from the 2020 Bakker et al. GWAS independently confirmed that intracranial aneurysm heritability is concentrated in endothelial cell epigenetic marks — exactly the cell type SOX17 controls.

The Evidence

The original discovery came from the landmark Bilguvar et al. 2008⁴⁴ Bilguvar et al. 2008
Susceptibility loci for intracranial aneurysm in European and Japanese populations, Nature Genetics genome-wide association study. Spanning Finnish, Dutch, and Japanese cohorts totalling more than 2,100 intracranial aneurysm cases and 8,000 controls, the study identified the chromosome 8q locus — with rs9298506-A as the risk allele — among three genome-wide significant hits (OR approximately 1.35 in the 8q range).

The 8q SOX17 association was confirmed in a larger Yasuno et al. 2010⁵⁵ Yasuno et al. 2010
Genome-wide association study of intracranial aneurysm identifies three new risk loci, Nature Genetics multi-cohort GWAS: 5,891 cases and 14,181 controls from European and Japanese populations. rs9298506-A reached p=1×10⁻¹² with OR 1.28 (95% CI 1.20–1.38) — each copy of the A allele raises intracranial aneurysm odds by approximately 28% relative to the protective G allele.

A Korean case-control and East-Asian meta-analysis⁶⁶ Korean case-control and East-Asian meta-analysis
Hong et al. 2018 World Neurosurgery pooling 5,100 IA cases and 7,930 controls confirmed the rs9298506 association in Asian populations: OR 1.19 (95% CI 1.07–1.32, p=0.0016) for the A allele risk direction, consistent across ancestry groups. The Bakker et al. 2020⁷⁷ Bakker et al. 2020
Nature Genetics cross-ancestry GWAS of 10,754 cases and 306,882 controls further validated that loci in this region contribute to intracranial aneurysm risk within a polygenic architecture, with heritability concentrated in endothelial cell biology.

A Deka et al. 2010⁸⁸ Deka et al. 2010
Stroke study of 406 familial IA cases found that the 8q11 SOX17 signal (rs10958409, in strong LD with rs9298506) interacted multiplicatively with smoking — a gene-environment interaction meaning the risk conferred by this locus is significantly amplified in smokers. This is one of the strongest gene-environment interactions documented for intracranial aneurysm risk.

The evidence is classified as strong: consistent replication across European and East Asian GWAS in independent cohorts, a clear biological candidate gene with an established vascular role, and documented gene-environment interaction with smoking.

Practical Actions

The A allele at rs9298506 is the most common allele globally (~81%), meaning the majority of people carry at least one copy. However, the per-allele OR of ~1.28 is real and clinically meaningful — it is comparable in magnitude to other established cardiovascular risk variants. For AA homozygotes, the cumulative effect of two risk alleles is particularly relevant when combined with other risk factors.

The two most important actionable modifiers of SOX17-locus aneurysm risk are: smoking cessation (the gene-environment interaction documented by Deka et al. means smoking specifically amplifies 8q11 locus risk) and blood pressure control (the primary hemodynamic driver of aneurysm formation and rupture regardless of genetic background). For individuals with a family history of intracranial aneurysm or subarachnoid hemorrhage, this genetic finding adds weight to the case for discussing proactive MRI angiography screening with a physician.

Interactions

rs9298506 is the second SOX17-region variant in this intracranial aneurysm panel; the other SOX17-region GWAS tag SNP rs10958409 (analyzed in the Deka 2010 Stroke study) is in linkage disequilibrium with rs9298506 and tags the same 8q11.23 susceptibility locus. These two SNPs should not be treated as additive independent risk signals — they reflect the same underlying association.

The SOX17 locus acts additively with other independently replicated intracranial aneurysm susceptibility loci, including rs1333040 at 9p21 (near CDKN2A/B, the most robustly replicated IA locus), rs700651 at 2q33.1 (BOLL), and rs767603 at 14q23. These loci operate through distinct pathway nodes — endothelial identity (SOX17), cell cycle senescence (9p21), RNA splicing regulation (2q33.1), and vascular wall regulatory elements (14q23) — and their risk contributions are additive in polygenic models. Individuals carrying risk alleles across multiple loci have substantially higher absolute risk than any single locus implies.

Your brain's response to stress depends on a continuous supply of new neurons in the hippocampus — a process called adult hippocampal neurogenesis. This region serves double duty: it encodes memory and, critically, it provides inhibitory control over the HPA axis¹¹ HPA axis
The hypothalamic-pituitary-adrenal axis: the hormonal cascade where the hypothalamus signals the pituitary, which signals the adrenal glands to release cortisol. Healthy hippocampal neurogenesis helps shut this response off. The gene STK24 — encoding a kinase called MST3 — turns out to be essential for keeping that factory running. Variants near STK24, including rs9556979, may influence how well the hippocampus maintains its stress-dampening capacity.

STK24 belongs to the germinal center kinase-III (GCK-III) subfamily of Ste20-related kinases. Unlike most brain-relevant genes that encode neurotransmitter receptors or ion channels, STK24 encodes a master regulator of brain architecture itself — controlling how neurons move into position, grow their dendrites, and form synapses during development and throughout life.

The Mechanism

The rs9556979 variant sits approximately 12 kilobases downstream of the STK24 gene, in a region classified as regulatory. Variants in this position can alter promoter activity, enhancer function, or transcription factor binding that fine-tunes STK24 expression in neural tissue.

Inside neurons, STK24/MST3 operates through at least two critical pathways. First, it regulates neuronal migration²² neuronal migration
The developmental process by which newly born neurons travel from their birthplace in the ventricular zone to their final position in the cortical layers. Correct positioning is essential for functional circuit formation. Tang et al. 2014³³ Tang et al. 2014
Tang J et al. Cdk5-dependent Mst3 phosphorylation and activity regulate neuronal migration through RhoA inhibition. J Neurosci, 2014 showed that MST3 is activated by Cdk5 phosphorylation at Ser79, then phosphorylates RhoA at Ser26 to suppress its GTPase activity — releasing the cytoskeletal brake that allows neurons to extend a leading process and migrate. Silencing Mst3 in developing mouse cortex trapped neurons in a disorganized multipolar state, unable to complete their journey.

Second, in mature neurons, MST3 promotes dendritic spine and synapse formation. Ultanir et al. 2014⁴⁴ Ultanir et al. 2014
Ultanir SK et al. MST3 kinase phosphorylates TAO1/2 to enable Myosin Va function in promoting spine synapse development. Neuron, 2014 found that MST3 phosphorylates TAO1/2 kinases, which direct the motor protein Myosin Va to dendritic spines. Depleting MST3 reduced spine density in hippocampal cultures and in intact layer 2/3 pyramidal neurons.

The 2025 animal model study provides the clearest link to mood and stress. Wu et al. 2025⁵⁵ Wu et al. 2025
Wu KY et al. Stk24 deficiency causes disrupted hippocampal neurogenesis and anxiety-like behavior in mice. Commun Biol, 2025 generated brain-specific Stk24 conditional knockout mice and found that deleting the gene reduced the number of TBR2+, NeuroD+, and DCX+ cells (markers of newborn neurons at successive stages of maturation) and NeuN+/BrdU+ co-labeled mature new neurons in the dentate gyrus. Under stress, these mice had significantly higher plasma corticosterone and greater c-FOS+ neuronal activation than wild-type controls, with upregulated CRH expression — a signature of impaired hippocampal inhibition of the HPA axis. Behaviorally, knockout mice spent more time in exposed areas (center of open field, light compartment of light-dark box), consistent with anxiety-like disinhibition.

The Evidence

Human genetic evidence for STK24's role in anxiety comes from two sources. A genome-wide study of psycho-emotional well-being in 30,063 Russians⁶⁶ 30,063 Russians
Yakovchik AY et al. Genetics of psycho-emotional well-being: genome-wide association study and polygenic risk score analysis. Front Psychiatry, 2024 identified rs9517326 — a neighboring STK24 variant — as significantly associated with HADS-A anxiety scores alongside PTPRN2 and DLGAP4, genes involved in excitatory neurotransmission. The study highlighted STK24's role in neurogenesis and synaptic function as the mechanistic basis.

At the population scale, the largest anxiety GWAS to date — Strom, Levey et al. 2024⁷⁷ Strom, Levey et al. 2024
Strom NI, Levey DF et al. Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling. medRxiv, 2024 — identified 58 loci for major anxiety disorders and underscored the role of genes affecting synaptic biology and neurogenesis. GWAS catalog data show rs9556979 is also associated with body shape measurements (p=3×10⁻¹⁰) and metabolic syndrome (p=1×10⁻¹⁴) — consistent with STK24's broader roles in stress physiology and the brain-metabolic axis.

Practical Implications

The evidence positions STK24 rs9556979 as a moderator of hippocampal resilience under stress. G allele carriers may have reduced STK24 expression in neural tissue, leading to modestly impaired adult hippocampal neurogenesis and a slightly less efficient brake on the HPA stress axis. The practical consequence is a stress response that tends to run somewhat longer and stronger — not a psychiatric diagnosis, but a biological predisposition worth knowing.

Interventions that directly stimulate hippocampal neurogenesis are relevant here: aerobic exercise is the most robustly validated, increasing BDNF and new neuron production within 4-6 weeks of consistent training. Dietary approaches that support BDNF (adequate omega-3 EPA/DHA, sufficient zinc and magnesium) and reduce neuroinflammation may also support hippocampal neurogenesis capacity.

Interactions

rs9556979 and FKBP5 rs1360780 operate through overlapping HPA axis pathways — STK24 affecting the neurogenic brake on cortisol release, and FKBP5 affecting the glucocorticoid receptor feedback loop. Carriers of risk alleles at both loci would be expected to show additive impairment in stress resolution.

BDNF rs6265 (Val66Met) is also relevant: since STK24 supports the structural substrate for hippocampal neurogenesis and BDNF provides the survival signal for new neurons, carriers of both the G allele at rs9556979 and the Met allele at rs6265 may have compounded reduction in adult neurogenesis capacity.